Literature DB >> 28043527

Overview of drug-resistant tuberculosis worldwide.

Ali A Velayati1, Parissa Farnia2, Amir M Farahbod1.   

Abstract

Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In 2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million people died. This is the real situation despite the well-structured treatment programs and availability of effective treatment options since the 1950s. The high mortality rate has been associated with other risk factors, such as the HIV epidemic, underlying diseases, and decline of socioeconomic standards. Furthermore, the problem of drug resistance that was recognized in the early days of the chemotherapeutic era raises serious concerns. Although resistance to a single agent is the most common type, resistance to multiple agents is less frequent but of greater concern. The World Health Organization estimated approximately 5% of all new TB cases involved multidrug-resistant (MDR)-TB. The estimation for MDR-TB is 3.3% for new cases, and 20.5% for previously treated cases. Failure to identify and appropriately treat MDR-TB patients has led to more dangerous forms of resistant TB. Based on World Health Organization reports, 5% of global TB cases are now considered to be extensively drug resistant (XDR), defined as MDR with additional resistance to both fluoroquinolones and at least one second-line injectable drug. XDR-TB had been reported by 105 countries by 2015. An estimated 9.7% of people with MDR-TB have XDR-TB. More recently, another dangerous form of TB bacillus was identified, which was named totally drug resistant (TDR-TB) or extremely drug resistant TB. These strains were resistant to all first- and second-line anti-TB drugs. Collectively, it is accepted that 2% of MDR-TB strains turn to be TDR-TB. This number, however, may not reflect the real situation, as many laboratories in endemic TB countries do not have proper facilities and updated protocols to detect the XDR or TDR-TB strains. Nevertheless, existing data emphasize the need for additional control measures, such as new diagnostic methods, better drugs, and more effective vaccines to prevent the spread of these strains around the world.
Copyright © 2016.

Entities:  

Keywords:  Drug-resistant tuberculosis (DR-TB); Epidemiology; Extensively drug-resistant tuberculosis (XDR-TB); Totally drug-resistant tuberculosis (TDR-TB)

Year:  2016        PMID: 28043527     DOI: 10.1016/j.ijmyco.2016.09.066

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  6 in total

1.  3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents.

Authors:  Nikum D Sitwala; Vivek K Vyas; Piyush Gedia; Kinjal Patel; Rania Bouzeyen; Saqib Kidwai; Ramandeep Singh; Manjunath D Ghate
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

2.  GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Authors:  Thomas H King; Crystal A Shanley; Zhimin Guo; Donald Bellgrau; Timothy Rodell; Synthia Furney; Marcela Henao-Tamayo; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

3.  High prevalence of multi drug resistant tuberculosis in people living with HIV in Western India.

Authors:  Neil Saldanha; Kiran Runwal; Charulata Ghanekar; Sunil Gaikwad; Shrivallabh Sane; Sanjay Pujari
Journal:  BMC Infect Dis       Date:  2019-05-08       Impact factor: 3.090

4.  Cytokine and Chemokine Concentrations as Biomarkers of Feline Mycobacteriosis.

Authors:  C O'Halloran; L McCulloch; L Rentoul; J Alexander; J C Hope; D A Gunn-Moore
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

5.  Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis.

Authors:  Svetlana G Frolova; Ksenia M Klimina; Ravinder Kumar; Aleksey A Vatlin; Deepak B Salunke; Pravin Kendrekar; Valery N Danilenko; Dmitry A Maslov
Journal:  Antibiotics (Basel)       Date:  2020-12-23

6.  Investigating the Antituberculosis Activity of Selected Commercial Essential Oils and Identification of Active Constituents Using a Biochemometrics Approach and In Silico Modeling.

Authors:  Katyna J Boussamba-Digombou; Maxleene Sandasi; Guy P Kamatou; Sandy van Vuuren; Rafal Sawicki; Zeynab Fakhar; Alvaro M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.